AEterna Zentaris (TSX:AEZS) Change In Receivables : C$0.20 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Change In Receivables?

AEterna Zentaris's change in receivables for the quarter that ended in Dec. 2023 was C$0.21 Mil. It means AEterna Zentaris's Accounts Receivable declined by C$0.21 Mil from Sep. 2023 to Dec. 2023 .

AEterna Zentaris's change in receivables for the fiscal year that ended in Dec. 2023 was C$0.20 Mil. It means AEterna Zentaris's Accounts Receivable declined by C$0.20 Mil from Dec. 2022 to Dec. 2023 .

AEterna Zentaris's Accounts Receivable for the quarter that ended in Dec. 2023 was C$0.09 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AEterna Zentaris's Days Sales Outstanding for the three months ended in Dec. 2023 was 50.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AEterna Zentaris's liquidation value for the three months ended in Dec. 2023 was C$20.50 Mil.

AEterna Zentaris Change In Receivables Historical Data

The historical data trend for AEterna Zentaris's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Change In Receivables Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.49

-1.31

0.15

0.80

0.20

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.23	0.28	0.26	-0.56	0.21

AEterna Zentaris Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.20 Mil.

AEterna Zentaris (TSX:AEZS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AEterna Zentaris's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.09	/	0.162	*	91
=	50.69

2. In Ben Graham's calculation of liquidation value, AEterna Zentaris's accounts receivable are only considered to be worth 75% of book value:

AEterna Zentaris's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	45.636	-	25.249	+	0.75 * 0.09	+	0.5 * 0.089
=	20.50

AEterna Zentaris Change In Receivables Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.